Macozinone - Ecole Polytechnique Federale de Lausanne/Nearmedic
Alternative Names: PBTZ-169; PBTZ169 NCPLatest Information Update: 28 Jan 2021
At a glance
- Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
- Developer NEARMEDIC
- Class Antituberculars; Cyclohexanes; Fluorinated hydrocarbons; Nitrobenzenes; Piperazines; Thiazines
- Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in Switzerland (PO, Liquid)
- 07 Sep 2020 Pharmacodynamics data from preclinical studies in Tuberculosis presented at the 30th Annual Congress of the European Respiratory Society (ERS-2020)
- 12 Sep 2019 Chemical structure information added